Drug intelligence / Profile preview

S3I-201

Development stage
Unknown
Lead developer
National Cancer Institute
Modality
Small Molecules
Administration
Intraperitoneal, Intravenous
01

Overview

S3I-201 (also known as NSC 74859 or SVI-201) is a cell-permeable, amidosalicylic acid-based small molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). Originally identified from the National Cancer Institute (NCI) chemical libraries through structure-based virtual screening, S3I-201 binds to the STAT3 Src Homology 2 (SH2) domain. This binding prevents STAT3 phosphorylation, dimerization, nuclear translocation, DNA binding, and transcriptional activation. S3I-201 is widely utilized as a chemical probe in preclinical research to investigate STAT3-dependent pathways in various cancers (including breast cancer, osteosarcoma, and head and neck squamous cell carcinoma) and inflammatory or autoimmune conditions. However, subsequent studies have revealed that S3I-201 can act as a non-selective covalent alkylating agent, modifying multiple intracellular proteins, which limits its utility as a highly selective STAT3 probe.

Other names
2-Hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid2-hydroxy-4-[[2-(4-methylphenyl)sulfonyloxyacetyl]amino]benzoic acidSTAT3 Inhibitor VISTAT-3 Inhibitor VISTAT 3 Inhibitor VISVI-201SVI201SVI 201
02

Targets

STAT1 (Signal transducer and activator of transcription protein 1)STAT3 (Signal Transducer and Activator of Transcription 3)STAT5A (STAT5)

Beyond the preview

Go deeper on S3I-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on S3I-201.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call